Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

[Effectiveness of serotonergic agonists in the treatment of obese patients].

Mendoza Espejo R, Díaz Pérez de Madrid J, Buitrago F.

Aten Primaria. 1995 Oct 15;16(6):364-6. Spanish.

PMID:
7488690
2.

Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.

Whigham LD, Dhurandhar NV, Rahko PS, Atkinson RL.

Int J Obes (Lond). 2007 May;31(5):850-7. Epub 2006 Dec 5.

PMID:
17146452
3.

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.

Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.

Int J Obes (Lond). 2008 Apr;32(4):692-9. Epub 2007 Dec 11.

PMID:
18071341
4.

[The treatment of the obese non-insulin-dependent patient with d-fenfluramine].

Daniele E, Coco MP.

Clin Ter. 1996 Apr;147(4):199-204. Italian.

PMID:
8766352
5.

Serotoninergic drug-induced weight loss in carbohydrate craving obese patients.

Toornvliet AC, Pijl H, Hopman E, Elte-de Wever BM, Meinders AE.

Int J Obes Relat Metab Disord. 1996 Oct;20(10):917-20.

PMID:
8910095
6.
7.

The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.

Ditschuneit HH, Flechtner-Mors M, Adler G.

J Cardiovasc Risk. 1996 Aug;3(4):397-403.

PMID:
8946272
8.
9.

A comparative trial of different regimens of fenfluramine and phentermine in obesity.

Steel JM, Munro JF, Duncan LJ.

Practitioner. 1973 Aug;211(262):232-6. No abstract available.

PMID:
4580610
10.

Balanced hypocaloric diet versus protein-sparing modified fast in the treatment of obesity: a comparative study.

Iselin HU, Burckhardt P.

Int J Obes. 1982;6(2):175-81. No abstract available.

PMID:
7095973
11.

Consumption of whole-grain cereals during weight loss: effects on dietary quality, dietary fiber, magnesium, vitamin B-6, and obesity.

Melanson KJ, Angelopoulos TJ, Nguyen VT, Martini M, Zukley L, Lowndes J, Dube TJ, Fiutem JJ, Yount BW, Rippe JM.

J Am Diet Assoc. 2006 Sep;106(9):1380-8; quiz 1389-90.

PMID:
16963343
12.

Predictors of weight loss during treatment with d-fenfluramine.

Toornvliet AC, Pijl H, Hopman E, Westendorp RG, Meinders AE.

J Intern Med. 1997 May;241(5):401-6.

13.

Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.

Anchors M.

Arch Intern Med. 1997 Jun 9;157(11):1270. No abstract available.

PMID:
9183245
14.

Appraisal of the clinical value of serotoninergic drugs.

Munro JF, Scott C, Hodge J.

Am J Clin Nutr. 1992 Jan;55(1 Suppl):189S-192S. Review.

PMID:
1728833
15.
16.

[Judicious use of anorectics].

Laurent-Jaccard A.

Schweiz Rundsch Med Prax. 1991 Feb 5;80(6):116-7. French.

PMID:
2003174
17.

Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine.

Glatz AC, Ehrlich M, Bae RS, Clarke MJ, Quinlan PA, Brown EC, Rada P, Hoebel BG.

Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):197-204.

PMID:
11812523
20.

Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability.

Curzon G, Gibson EL, Oluyomi AO.

Trends Pharmacol Sci. 1997 Jan;18(1):21-5. Review.

PMID:
9114726

Supplemental Content

Support Center